End-To-End Workflow Integration For Monoclonal And Bispecific Antibody Development

By Ada Yee, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

Biopharma R&D teams are generating more complex data than ever, especially as antibody discovery expands into diverse, multi‑specific formats. But the volume and fragmentation of these datasets—spanning sequence design, screening, engineering, analytics, and manufacturability—make it increasingly difficult for scientists to work efficiently or extract meaningful insights. These challenges are magnified when teams operate across global sites with disconnected systems and inconsistent data practices.

Discover how a centralized digital backbone can transform end‑to‑end antibody discovery by unifying workflow data, standardizing processes, and enabling automation and real‑time collaboration, as well as how one large biopharma organization achieved dramatic gains in speed, data quality, and scientific productivity.

Learn how integrated, FAIR‑aligned infrastructures set the stage for AI‑ready R&D and help organizations scale innovation.